RT Journal Article
SR Electronic
T1 Voice of the patient: Emergence of new motor and non-motor symptoms in early Parkinson’s Disease?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21258883
DO 10.1101/2021.06.21.21258883
A1 Michelle H.S. Tosin
A1 Tanya Simuni
A1 Glenn T. Stebbins
A1 Jesse M. Cedarbaum
YR 2021
UL http://medrxiv.org/content/early/2021/06/24/2021.06.21.21258883.abstract
AB Objective To explore the utility of using patient reported emergence of new symptoms (ES) as an outcome measure during the early phase of the disease.Methods We analyzed data from MDS-UPDRS Part IB and Part II from the Safety, Tolerability, and Efficacy Assessment of Isradipine for PD (STEADY-PD3) study, with at least one annual follow-up over two years. We divided the sample into categories of follow-up visit (between 0 and 12-months, and 13 and 24-months) and the number of ES for each part of the scale between participants who started symptomatic treatment and those who did not (STx-yes/no). We assessed ES differences between participants STx in each follow-up visit using Mann-Whitney U test, and the Kaplan-Meier analyses.Results Of 331 participants observed for months 0 to 12, 288 (87%) developed ES, and 182 (55%) started STx. For Part IB, the median number of ES did not significantly differ between the STx groups (Z=-0.86, p = 0.39), while for Part 2, the number of ES was significantly higher for the STx-yes group (Z=-2.38, p=0.02). Of 148 participants who continued to be observed for months 13 to 24, 114 (77%) developed ES, and 62 (42%) started STx. For Part IB, the median number of ES did not significantly differ between the STx groups (Z=-0.33, p = 0.74), while for Part 2, the number of ES was significantly higher for the STx-yes group (Z=-2.25, p=0.02).Conclusions Assessing ES among patient-reported experiences of daily living may provide a useful marker for tracking PD progression.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02168842Funding StatementThe authors recieved no third party support for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Rochester IRB: https://www.rochester.edu/ohsp/rsrb/ All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on NINDS clinical trials repository Archived Clinical Research Datasets | National Institute of Neurological Disorders and Stroke (nih.gov) https://c-path.org/programs/cpp/ https://amp-pd.org/whole-genome-data https://www.ninds.nih.gov/sites/default/files/sig_form_revised_508c.pdf